**AMENDMENTS TO THE SPECIFICATION**:

*On page 1, after the title, please insert the following new paragraph as follows*:

This application is a National Stage Application of PCT/JP2005/008239, filed April 28, 2005.

*Please amend paragraph [0089] as follows*:

**[0089]** A method of identifying a compound that inhibits the phosphorylation of TERT by an active MAPKAPK3 can be carried out concretely by selecting the conditions that allow for the interaction of a test compound with an active MAPKAPK3 and/or TERT, contacting the test compound with the active MAPKAPK3 and/or TERT under the condition, employing a system that uses a signal and/or a marker capable of detecting the phosphorylation of TERT by the active MAPKAPK3, and then detecting the presence, the absence or the change of the signal and/or the marker. For example, in the case that the signal generated by the phosphorylation of TERT by the active MAPKAPK3 or the marker of the ~~binding~~ phosphorylation shows a change, such as reduction or disappearance, when contacting a test compound with MAPKAPK3 and/or TERT, it can be determined that the test compound inhibits the phosphorylation of TERT by the active MAPKAPK3. The conditions that allow for the interaction of a test compound with MAPKAPK3 and/or TERT may be a condition in vitro or in vivo. For example, a cell in which MAPKAPK3 is coexpressed with TERT may be used.

*Please amend paragraph [0091] as follows*:

**[0091]** A method of identifying a compound that inhibits the phosphorylation of TERT by an active MAPKAPK3 can be also carried out using an assay system in which the aforementioned

method for carrying out the phosphorylation of TERT by an active MAPKAPK3 and detection of the phosphorylated TERT is utilized. In the case that the phosphorylation of TERT by the ~~test compound~~ active MAPKAPK3 under co-existence of the test compound in such a system is reduced or disappeared comparing to the phosphorylation in the absence of the test compound, it can be determined that the test compound inhibits the phosphorylation of TERT by the active MAPKAPK3.

*Please amend paragraph [0098] as follows*:

**[0098]** The telomerase activity has been observed in a large number of tumors regardless of the kinds of tumors. Thus, it is believed that the pharmaceutical composition according to the present invention is effective for inhibition of proliferation of a variety of cancer cells. Therefore, in the case where the present pharmaceutical composition is used for a cancer disease, the kind of a tumor to be targeted is not particularly limited, and it can be applied to either solid tumor or non-solid tumor. The kind of a solid tumor or non-solid tumor is also not particularly limited, and the present pharmaceutical composition can be applied to all kinds of tumors having telomerase activity. A cancer disease is exemplified by a solid tumor such as a stomach cancer, esophageal cancer, colon cancer, small intestinal cancer, duodenal carcinoma, lung cancer, liver cancer, gallbladder cancer, pancreatic cancer, renal cancer, bladder cancer, oral cancer, osteocarcinoma, skin cancer, breast cancer, uterine cancer, prostate cancer, brain tumor, neuroblastoma and the like, or a non-solid tumor such as leukemia, malignant lymphoma, and the like. However, the application target of the present pharmaceutical composition is not limited to these diseases. More preferably, the present pharmaceutical composition can be further applied to a cancer disease in which the activation of MAPKAPK3 and the enhanced expression of its

gene are observed, or a cancer disease in which the activation of a protein involving in the activation of MAPKAPK3 is observed. It has been reported that p38 known to activate MAPKAPK3 is activated in a breast cancer tissue and a non-small lung cancer tissue. Furthermore, it has been reported that ERK known to activate MAPKAPK3 is activated in a cancer tissue such as breast cancer, renal cell carcinoma, acute leukemia, glia cell tumor, prostate cancer, neuroepithelioma, squamous carcinoma, liver cell carcinoma and the like. Therefore, the present pharmaceutical composition is preferably applied to breast cancer, renal cell carcinoma, acute leukemia, glia cell tumore, prostate cancer, neuroepithelioma, squamous carcinoma, liver cell carcinoma, ~~prostate cancer~~ and non-small lung cell cancer, and is more preferably applied to breast cancer.